Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multi-pathogen specific T-lymphocytes (University of Sydney)
- Development stage
- Unknown
- Lead developer
- University of Sydney
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Multi-pathogen specific T-lymphocytes is an investigational adoptive cell therapy developed by the University of Sydney for the treatment of refractory viral and fungal infections in immunocompromised patients following allogeneic stem cell or solid organ transplantation. The therapy consists of HLA-matched, third-party donor-derived T-lymphocytes that are expanded ex vivo using peptide stimulation and CD137-based selection to target cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus, and fungal pathogens including Aspergillus and Candida species. By providing a "banked" source of pre-manufactured, partially HLA-matched effector cells, this approach aims to restore cellular immunity rapidly in patients who have failed standard antiviral or antifungal treatments. The product is currently being evaluated in the R3ACT clinical trial.
- Other names
- Virus- and fungus-specific T-lymphocytesVSTsFSTsThird-party donor-derived T-cellsVirus- and fungus-specific cytotoxic T-lymphocytes
02
Targets
Epstein-Barr virus-derived peptide antigens presented by human leukocyte antigenAdenovirus-derived peptide antigens presented by HLACytomegalovirus-derived peptide antigens presented by human leukocyte antigenpMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on multi-pathogen specific T-lymphocytes (University of Sydney).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multi-pathogen specific T-lymphocytes (University of Sydney).